Physician profile
David M Calimag
NPI 1922112184
$2,033.19
in general payments reported to CMS, 2019-2025
27 companies · $838 in 2025
The $838 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $29.07 · 2021: $93.68 · 2023: $225 · 2024: $742 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $376.40 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $199.52 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $168.90 | 2024-2025 | |
| Abbvie INC. | $153.92 | 2021-2025 | |
| Lilly USA, LLC | $125.18 | 2023-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $120.37 | 2024-2025 | Voquezna |
| Banner Life Sciences, LLC | $115.81 | 2023-2024 | |
| Dexcom, INC. | $108.83 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.78 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $73.20 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $72.39 | 2024-2025 | Auvelity, Symbravo |
| E.R. Squibb & Sons, L.L.C. | $52.38 | 2023-2024 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $45.03 | 2024-2025 | |
| Astellas Pharma US INC | $43.54 | 2024-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $42.11 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $30.79 | 2025 | Inspire |
| Currax Pharmaceuticals LLC | $29.52 | 2023-2024 | Contrave, Onzetra Xsail |
| Corcept Therapeutics | $28.36 | 2025 | Korlym |
| Medtronic, INC. | $24.57 | 2023 | Venaseal |
| Abbott Laboratories | $22.60 | 2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $20.69 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.39 | 2025 | Amvuttra |
| Biohaven Pharmaceuticals, INC. | $17.70 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2024 | Xifaxan |
| Lundbeck LLC | $16.57 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.69 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $13.35 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Calimag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.